52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Saxagliptin is a new investigational medication being developed for treatment of type 2
 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in
 addition to metformin and compare to sulphonylurea in addition with metformin.
Inclusion Criteria:

 -  Diagnosed with type 2 diabetes,

 -  Treatment with metformin alone on stable doses of 1500 mg or higher per day for at
 least 8 weeks prior to Visit 1,

 -  HbA1c >6.5% and ≤10.0%

 Exclusion Criteria:

 -  Type 1 diabetes,

 -  history of diabetic ketoacidosis or hyperosmolar non-ketonic coma,

 -  Insulin therapy within one year of enrolment (with the exception of insulin therapy
 during a hospitalization or use in gestational diabetes)